Advertisement
Singapore markets closed

  • Straits Times Index

    3,272.72
    +47.55 (+1.47%)
     

  • S&P 500

    5,060.06
    +49.46 (+0.99%)
     

  • Dow

    38,386.38
    +146.40 (+0.38%)
     

  • Nasdaq

    15,659.20
    +207.90 (+1.35%)
     

  • Bitcoin USD

    66,815.34
    +526.95 (+0.79%)
     

  • CMC Crypto 200

    1,436.40
    +21.64 (+1.53%)
     

  • FTSE 100

    8,029.59
    +5.72 (+0.07%)
     

  • Gold

    2,336.70
    -9.70 (-0.41%)
     

  • Crude Oil

    82.08
    +0.18 (+0.22%)
     

  • 10-Yr Bond

    4.5820
    -0.0410 (-0.89%)
     

  • Nikkei

    37,552.16
    +113.55 (+0.30%)
     

  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     

  • FTSE Bursa Malaysia

    1,561.64
    +2.05 (+0.13%)
     

  • Jakarta Composite Index

    7,110.81
    +36.99 (+0.52%)
     

  • PSE Index

    6,506.80
    +62.72 (+0.97%)
     

Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?

Daniel Collins
Updated
Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?

On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.

Continue reading